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Abstract Activation of phospholipase A2 (PLA2) occurs follow- 
ing mitogenic stimulation of cells. This study examined PLA2 
activation during liver regeneration. Increased activity was de- 
tected within 1 h after partial hepatectomy, was maximal by 6 h, 
and returned to control levels by 24 h. Fractionation of cell-free 
extracts revealed multiple peaks of PLA a activity. One peak 
appeared identical to the previously described cPLA2, and was 
modestly stimulated during regeneration. A higher molecular 
weight form (hPLA2) was stimulated ~5-fold during regeneration. 
This enzyme was Ca2+-dependent and selective for arachidonoyl- 
phosphatidylethanolamine. The activation of this novel form of 
PLA2 represents an early event in liver regeneration, and is likely 
to contribute to the proliferative response. 
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1. Introduction 
Liver regeneration has been used as a model for regulated 
proliferation for many years. In rats, following surgical re- 
moval of 70% of the liver mass, the remaining hepatocytes 
behave as a synchronized cell population, and are activated to 
undergo mitosis. While the factors ignaling both the initiation 
and termination of proliferation have not been conclusively 
established, a number of growth factors including hepatocyte 
growth factor, insulin, EGF, glucagon, and vasopressin appear 
to be necessary for this process (see [1] for review). In addition, 
a number of intracellular signaling events have been shown to 
occur following partial hepatectomy. Within 10-60 min there 
is an induction of c-fos protooncogene mRNA [2]. Protein 
kinase C has been shown to translocate from the cytosol to 
particulate fractions within 30-60 rain [3]. We have previously 
shown that a mitogen-stimulated s rine kinase which phospho- 
rylates ribosomal protein $6 is activated within 2 h following 
surgery [4]. All of these vents temporally precede the entry into 
S phase, and the replication of DNA which occur approxi- 
mately 18 h after surgery, and it is therefore likely that these 
events represent part of the programmed response resulting in 
proliferation. 
The activation of phospholipase A 2 (PLA2) has been ob- 
served to follow mitogenic stimulation of a variety of cell types 
in culture. In several cases it has been convincingly demon- 
strated that stimulation of arachidonic acid release is an oblig- 
atory event for cell growth. In 3T3 cells, stimulated arachidonic 
*Corresponding author. Fax: (1) (303) 270-4852. 
Abbreviations: PLA2, phospholipase A2; PC, phosphatidylcholine; PE,
phosphatidylethanolamine; HEPES, 4-(2-hydroxyethyl)-l-piperazine- 
ethanesulfonic acid; EGTA, [ethylenebis(oxyethylenenitrilo)]tetra- 
acetic acid. 
acid release through PLA2 has been shown to be required for 
mitogenesis [5]. Enhanced arachidonic acid release has also 
been observed in transformed cells. In v-ras transformed cells 
Bar-Sagi and co-workers have shown that PLA2 was activated 
following H-ras transformation of quiescent rat embryo fibro- 
blasts [6], and appeared to specifically co-localize with the ras 
protein in these cells [7], suggesting an interaction between 
PLA 2 and ras protein. Arachidonic acid has also been shown 
to modulate the interaction between ras and rasGTPase activat- 
ing protein (rasGAP) [8]. 
PLA 2 activation has also been associated with cell injury. 
Membrane breakdown and release of free fatty acids has been 
observed following ischemic injury in kidney, heart, and liver 
[9,10]. In rabbit renal proximal tubules anoxia has been shown 
to result in activation of PLA 2 [11], and PLA2 activity is mod- 
ulated during renal ischemia and reperfusion [12]. A novel 
CaZ+-independent form of the enzyme specific for plasmalogens 
is activated uring myocardial ischemia [13]. 
In hepatocytes, arginine vasopressin has been shown to 
acutely stimulate release of arachidonic acid [14]. PLA 2 stimu- 
lation has also been shown to occur following exposure of 
hepatocytes to carbon tetrachloride [15]. Neither the mecha- 
nism of regulation, nor the specific forms of PLA 2 involved 
have been identified. 
We report here the identification of three isoforms of PLA2 in 
liver extracts. One of these isoforms appears to be similar to the 
hormonally regulated cPLA2 previously described [16,17,18]. 
However, a second, high-molecular weight form appears to 
represent a novel isoform of PLA2 whose activity is markedly 
stimulated uring the early stages of liver regeneration. 
2. Experimental 
2.1. Animal surgery 
Partial hepatectomies were performed on male Sprague Dawley rats 
(120-250 g) following ether anesthesia as previously described [4]. Sham 
operations involved performance ofa laparotomy followed by manipu- 
lation, but not removal of the liver. All surgery was performed before 
10.30 h. At various times following surgery, animals were sacrificed. 
The liver remnants were removed, rinsed in ice-cold phosphate buffered 
saline, cut into several pieces and frozen in liquid nitrogen. 
2.2. Preparation and fractionation of extracts 
Pieces of liver were homogenized in 50 mM HEPES, pH 7.5, 1 mM 
EDTA, 1 mM EGTA, 250 mM sucrose, 20 /IM pepstatin, 20 ¢tM 
leupeptin, 100 /tM phenylmethylsulfonyl fluoride, and 1000 U/ml 
aprotinin, using a Potter-Elvesjem otor-driven pestle. Soluble xtracts 
were prepared by differential centrifugation as previously described 
[16], and matched for protein concentration. Equal amounts of extract 
protein from regenerating and sham-operated liver were fractionated 
by Pharmacia Superose 12 gel filtration chromatography. Extracts con- 
taining 2-5 mg of total protein were loaded on the column, which had 
previously been calibrated and equilibrated in 50 mM HEPES, pH 7.5, 
1 mM EGTA, 1 mM EDTA, 150 mM NaC1, as previously described 
[12]. 0.5 ml of extract was loaded on the column (24 ml) and 0.5 ml 
fractions were collected. Fractions were assayed for PLA2 activity as 
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previously described [16]. A portion of each fraction was used for 
immunoblotting (see below). Peaks recovered from the gel filtration 
column were further fractionated by Mono-Q anion exchange. Peak 
fractions were loaded on the column which had been equilibrated in 50 
mM HEPES, pH 7.5, 1 mM EGTA, 1 mM EDTA. The column was 
washed until the absorbance at280 nm reached baseline (approximately 
10 ml). Proteins were then eluted with a 35 ml linear NaC1 gradient from 
0 to 0.6 M; 1 ml fractions were collected and assayed for PLA2 
activity. 
2.3. PLA 2 activity assays 
In a reaction volume of 40 pl, column fractions were incubated with 
15 /tM 1-palmitoyl-2-[14C]-araehidonoyl-phosphatidylethanoloamine 
(PE) or -phosphatidylcholine (PC) (specific activity = 57 mCi/mmol) in 
the presence of 4 mM CaCI2 (in excess of EDTA and EGTA) and 5% 
dimethyl sulfoxide for 30 rain at 37°C. The reaction was quenched with 
addition of 40 pl unlabeled arachidonic acid (500 /~g/ml) in etha- 
nol:acetic acid (98:2), and 50 ,ul of each sample was spotted 
onto Whatman LK5D Silica Gel TLC plates. The plates were developed 
in ethyl acetate/isooctane/acetic acid/water (55:75:8: 100) from 
which the lower, aqueous phase had been removed. Plates were stained 
with iodine vapor, and arachidonic acid peaks and PE or PC peaks were 
scraped with a razor blade into vials and counted by liquid scintillation 
counting in the presence of 250 pl water and 5 ml Opti-Fluor. Results 
are expressed as pmol/min. For assays using other substrates, the ap- 
propriate substrate was used at the same concentration. For studies 
examining divalent metal dependency and activation by NaCI, 4 mM 
MgCI 2, 4 mM MnCI 2 or 1 M NaCI was substituted for the 4 mM 
CaC12. 
2.4. Determination of calcium dependency 
Fractions from the gel filtration column (peaks I and II) were diluted 
in EGTA/Ca ~+ buffers containing various concentrations of Ca 2+. PLA2 
activity was assayed using PE as a substrate, as described above. Actual 
Ca 2+ concentrations were determined using fura-2 [19]. 
2.5. Immunoblotting 
Superose 12 column fractions from 5 mg of regenerating livers ex- 
tracts were run on SDS-polyacrylamide g ls and transferred tonitrocel- 
lulose. Blots were probed with a polyclonal antibody raised against a 
recombinant fragment of the cPLA2 molecule [20], followed by ~25I- 
protein A. As a positive control 10 ng of recombinant purified cPLA2 
was used. 
2.6. Materials 
Radiolabeled phospholipids were from Amersham Corp. or Dupont- 
New England Nuclear. Unlabeled phospholipids, arachidonic acid, and 
standards for thin layer chromatography, as well as standard chemicals 
for buffers were from Sigma. Prepacked Mono-Q (HR 5/5) and Super- 
ose 12 columns were from Pharmacia LKB Biotechnology Inc. Protein 
was measured using a Bio-Rad protein kit. Molecular weight markers 
for polyacrylamide g ls were from Bio-Rad. Nitrocellulose paper (TM- 
NC4) and all reagents for SDS-PAGE and immunoblotting were pur- 
chased from Hoefer Scientific Instruments and Bethesda Research Lab- 
oratories. 
3. Results 
3.1. Activation of  PLA 2 activity during liver regeneration 
Soluble extracts were prepared from livers at various times 
following partial hepatectorny. Extracts were matched for 
protein concentrat ion and assayed for PLA2 activity using 1- 
palmitoyl-2-[~4C]-arachidonoyl-PC or 1-palmitoyl-2-[14C]-ara - 
chidonoyl-PE as substrate in the presence of 4 mM Ca 2.. As 
shown in Fig. 1, an increase in PLA 2 activity was observed 
within an hour  after surgery compared to sham-operated ani- 
mals. Enhanced specific activity was detected using either 
[14C]arachidonoyl-PC or [14C]arachidonyl-PE as substrate, al- 
though a much larger increase was detected with [~4C]ara- 
chidonoyl-PE. Maximal increase occurred at 4-6 h, and PLA 2 
activity returned to sham levels by 24 h. Activity from sham- 
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Fig. 1. Time course of stimulation of PLA2 activity in regenerating 
versus ham-operated livers. Cell-free extracts were prepared from rats 
at the indicated times following surgery. Sham animals received a lapa- 
rotomy followed by manipulation, but not removal of the liver. Extracts 
were matched for protein and PLA 2 activity determined by measuring 
the rate of hydrolysis of arachidonic acid from exogenous [~4C]ara- 
chidonoyl-PC (Panel A) or [14C]arachidonoyl-PE (Panel B). Results 
represent the means of triplicate determinations from 3 separate ani- 
mals at each time point. *P<0.05 vs. Sham. 
operated animals was identical to control animals not undergo- 
ing any surgical procedures, and did not change as a function 
of time. Extracts assayed in the absence of exogenously added 
Ca 2+ showed little activity (data not shown). 
3.2. Fractionation of  liver extracts 
To characterize the specific isoforms of PLA 2 which are 
activated uring regeneration, extracts prepared from the re- 
generating livers of rats sacrificed 4 and 6 h after surgery, and 
from sham-operated animals were fractionated by FPLC gel 
fi ltration on a Superose 12 column. Fractions were assayed for 
PLA 2 activity using either [~4C]arachidonoyl-PE or -PC, in the 
presence of 4 mM Ca 2+. When [J4C]arachidonoyl-PC was used 
as a substrate, a single major peak of activity (hereafter referred 
to as peak II) was observed (Fig. 2A), and a small increase in 
activity was apparent in regenerating compared to sham livers. 
However, with [l~C]arachidonoyl-PE as the substrate, three 
peaks of activity were observed, all of which were stimulated 
in regenerating livers compared to sham. The major activity 
with [14C]arachidonoyl-PE migrated as a high-molecular weight 
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Fig. 2. Fractionation of extracts from regenerating and sham-operated 
liver. (A) Superose 12 gel filtration fractionation of liver extracts and 
determination of PLA2 activity in fractions. One half ml of extract 
containing approximately 5 mg protein was loaded on the column 
which had been calibrated with the following standards: BD-blue dex- 
tran (Mr = 6 x 106), BSA-bovine serum albumin (Mr = 66,000), OA- 
ovalbumin (Mr = 43,000), and KFC-potassium ferricyanide. Fractions 
(0.5 ml) were collected and assayed for PLA2 activity as described in 
section 2. (B) Immunoblot of Superose 12 fractions using antibody 
directed against he human 85 kDa cPLAz. A portion of the indicated 
fractions obtained in Panel A was separated on SDS-PAGE, and blot- 
ted with anti-cPLA2 antibody, followed by ~25I-protein A. Ten ng of 
human recombinant cPLA 2 was  loaded as a positive control. (C) Mono- 
Q anion exchange chromatography. Peak I recovered from the Super- 
ose 12 column (Fractions 8.5-10 ml) was diluted and loaded on a 
Mono-Q column. Proteins were eluted with a 35 ml gradient from 0 to 
0.6 M NaC1. Fractions (1 ml) were assayed for PLA~ activity using 
[14C]arachidonoyl-PE asdescribed above. 
protein just past the excluded volume of the column (peak I); 
this activity was stimulated approximately 5-fold in regenerat- 
ing liver. A peak corresponding to the major [14C]arachidonoyl- 
PC peak was modestly stimulated (peak II), and a third peak 
(peak III) appeared at low apparent molecular weight. This 
peak was not further characterized. 
The migration position of peak II is very similar to that of 
purified cPLA 2 isolated from rat kidney or mesangial cells [16]. 
To further examine the relationship between isoforms of PLA2 
detected in regenerating liver and cPLA2, the Superose 12 col- 
umn fractions were analyzed by immunoblotting, using a poly- 
clonal antibody raised against recombinant cPLA 2 [20]. This 
antibody recognizes the rat form ofcPLA2, a 110 kDa polypep- 
tide on SDS polyacrylamide gels, in both kidney and glomeru- 
lar mesangial cell extracts (data not shown). Fig. 2B shows that 
this antibody recognized a 110 kDa protein in fractions corre- 
sponding to peak II (12-14 ml fractions), but not peak I (8-10 
ml fractions). 
To confirm that peak I represented a single enzymatic spe- 
cies, fractions from the gel filtration column (8.5-10 ml) were 
pooled and fractionated by FPLC Mono-Q anion exchange, 
utilizing a linear NaC1 gradient. A single peak of PLA2 activity 
eluted at about 0.15 M NaC1 (Fig. 2C). Previous studies have 
shown that purified cPLA2 elutes from this column at approx- 
imately 0.37 M NaC1 using the same buffer conditions [16]. 
3.3. Substrate specificity and divalent cation requirement 
To characterize the substrate specificity of peak I, appropri- 
ate fractions were pooled as above and activity determined 
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Fig. 3. (A) Substrate and ion selectivity of peak I. Peak I recovered from 
the Superose 12 column was diluted with 50 mM HEPES, pH 7.5, I mM 
EDTA, 1 mM EGTA, and activity against various ubstrates (15 pM) 
was determined as described above in the presence of 4 mM of divalent 
cation salts, 1 M NaC1, or chelators alone (none). (B) pH dependence 
of peak I PLA2 activity. Activity was determined using [~4C]ara- 
chidonoyl-PE as a substrate and adjusting the pH with either Tris base 
or acetic acid. Results represent the mean of triplicate determinations 
with the standard error indicated. 
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Fig. 4. Dependence of peak I PEAs activity on Ca 2+ concentration• Peak 
I recovered from the Superose 12 column was diluted with 50 mM 
HEPES, pH 7.5, 1 mM EDTA, 1 mM EGTA. Various amounts of 
buffer or 20 mM CaC12 were added to obtain 200 #1 aliquots at each 
Ca 2+ concentration• PLA2 activity was determined using [t4C]ara- 
chidonoyl-PE as a substrate as described above. A portion of each 
aliquot was used to determine the actual free Ca 2+ concentration using 
fura-2. 
against phospholipids with different headgroups (ethanol- 
amine, choline, or inositol), and with different unsaturated fatty 
acids at the sn-2 position (arachidonate, linoleate, or oleate) 
(Fig. 3A). The data show a selectivity for ethanolamine as the 
headgroup, and for arachidonate asthe sn-2 fatty acid. 
When activity was assayed in the presence of divalent cations 
other than Ca 2+, a clear selectivity for Ca 2+ was seen when the 
phosphatidylethanolamine lipidswere used as substrates. Such 
selectivity was not clearly seen with phosphatidylcholine lipid, 
which, however, was a poor substrate for the enzyme under all 
conditions assayed. Activity against he 1-stearoyl-2-[~4C]-ara- 
chidonoyl-phosphatidylinositol was slightly higher, but was not 
dependent upon divalent cations and was, in fact, somewhat 
inhibited by them (Fig. 3A). This activity may therefore be 
distinct from the activity against phosphatidylethanolamine lip- 
ids, perhaps representing coelution with a distinct, Ca2+-inde - 
pendent phosphoinositidase. 
Further, in contrast to cPLA 2, which is activated under high- 
salt conditions [21], activity of peak I in the presence of 1 M 
NaC1 was strongly inhibited. In contrast to the secreted PLA2's, 
peak I was relatively insensitive to disruption of disulfide 
bonds, demonstrating only a 15% decrease in activity after 
5 rain of treatment with 50 mM DTT at 37°C (not shown). The 
pH sensitivity of peak I favored the alkaline range (Fig. 3B). 
3.4. Ca 2+ dependence 
To determine the Ca 2+ dependence of peak I, appropriate 
fractions (8.5-10 ml) from the Superose 12 column were pooled, 
and PLA, activity against 1-palmitoyl-2-[~4C]-arachidonoyl-PE 
was assayed over a wide range of Ca 2÷ concentrations (Fig. 4). 
Peak I required relatively high concentrations of Ca 2+ for enzy- 
matic activity, with the half-maximal concentration for activa- 
tion occurring at approximately 500 pM. This is significantly 
higher than the half-maximal CaZ+concentration f r cPLA2 
which is approximately 500 nM [16]. 
3.5. Sensitivity to known PLA2 inhibitor 
A trimethyl ketone analogue of arachidonic acid 
(AACOCF3) has recently been shown to strongly inhibit the 
human platelet cPLA2 but not the low molecular weight, secre- 
table sPLA 2 [22]. AACOCF3 was a potent inhibitor of both 
peak I and peak I! activity (Fig. 4A). Peak II was somewhat 
more strongly inhibited by AACOCF3, with 50% inhibition 
occurring at approximately 7 #M, and 80% inhibition occurring 
at 30 pM. For peak I, half-maximal inhibition was observed at 
approximately 15 #M AACOCF3, and 60% inhibition at 30 
#M. The methyl ketone derivative of arachidonic acid 
(AACOCH3) partially stimulated peak II activity at low con- 
centrations and had a minor inhibitory effect at 30 pM (Fig. 
4B). In contrast this compound was a potent inhibitor of peak 
I, with half-maximal inhibition occurring at approximately 15 
¢tM, and 70% inhibition at 30 pM (Fig. 5). 
4. Discussion 
The data presented suggest that multiple isoforms of PLA 2 
are present in rat liver extracts• One of these, designated aspeak 
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Fig. 5. Effect of trifluoroketone (AACOCF3) and methyl ketone 
(AACOCH3) araehidonic acid analogues on PLA 2 activities of peaks 
I and II. Pooled fractions from the Superose 12 column (peak I = frac- 
tions 8.5-10 ml, peak II = fractions 12.5-14.5 ml) were incubated with 
various concentrations of AACOCF 3 (Panel A) or AACOCH 3 (Panel 
B), the 300 #M stocks of which had been sonicated immediately before 
adding. PLA2 activity using [14C]arachidonoyl-PE wasdetermined. 
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II appears to be the liver homolog of cPLA2 [16,17,23,24]. Its 
migration position on both anion exchange and gel filtration 
are identical to the kidney form of cPLA2, and it is recognized 
by antibodies raised against he human cPLA2. The second 
form, designated peak I, is greatly stimulated within the first 
several hours of liver regeneration. This enzyme appears to 
represent an novel form of PLA2, not previously well character- 
ized. By a number of criteria it can be distinguished from 
cPLA2, the best characterized high-molecular weight form of 
PLA2. Peak I shows much greater activity towards ara- 
chidonoyl-PE than PC, as distinct from cPLA 2 which has ap- 
proximately equal activity against either substrate. It elutes 
earlier from anion exchange columns, is inhibited rather than 
activated by 1 M NaC1, and migrates at a higher molecular 
weight by gel filtration. Specific antibodies against cPLA2 do 
not appear to recognize this enzyme. 
This novel form appears to require much higher concentra- 
tions of Ca 2+ for activation in vitro than does cPLA 2 [25]. In 
fact, the Ca 2+ dependency of this enzyme is similar to the Ca 2+ 
requirements of the sPLA2 family of enzymes [26]. However, 
our data strongly suggest that peak I is not an aggregate of 
sPLA2. On two successive fractionation procedures the enzy- 
matic activity migrates as a single peak, with no detectable 
breakdown. Secondly, the sensitivity of peak I to inhibitory 
arachidonic acid analogs is very different from sPLA 2. These 
compounds are poor inhibitors of sPLA2 [22], but potent inhib- 
itors of peak I. In fact the methyl ketone derivative is a more 
potent inhibitor of peak I than of cPLA 2. Finally, peak I is 
insensitive to reducing agents. It is therefore more likely that 
peak I represents a novel form of PLA2, distinct from both 
cPLA2 and sPLA 2 specific to certain tissues. We have tenta- 
tively designated this enzyme hPLA2 (hepatic PLA2). 
Since the Ca 2+ dependency of this enzyme is so high, it raises 
the question as to how it is activated under normal or growth 
factor-stimulated l vels of Ca 2+. It is conceivable that interac- 
tions with other proteins or additional cofactors regulate the 
Ca 2+ dependency, allowing activation at more physiologic Ca 2+ 
concentrations. Alternatively, during the process of tissue dis- 
ruption and fractionation we have damaged the enzyme and 
altered its true Ca 2+ dependency. 
The mechanisms causing activation of PLA2 during liver 
regeneration remain to be determined. The kinetics of the in- 
crease in activity (detectable at 1 h following surgery) suggest 
that post-translational alteration of pre-existing enzyme is 
likely to be involved. It has been shown that cPLA2 is 
phosphorylated onserine residues in response to growth factor 
stimulation [27]. We and others have recently demonstrated 
that both protein kinase C and p42 MAP kinase can phospho- 
rylate and activate purified human cPLA2 [28,29]. Both of these 
protein kinases have been shown to be activated within the first 
hour during liver regeneration [30] and therefore are potential 
candidates mediating the observed activation of peak I. The 
observation that PLA2 activity is rapidly increased uring liver 
regeneration suggests an important role for arachidonic acid or 
its metabolites in the regenerative r sponse. Alternatively, lyso- 
phospholipids produced by PLA2 may be converted to lyso- 
phosphatidic acid, which has mitogenic properties [31]. 
To our knowledge, this is the first demonstration f activation 
of PLA 2 associated with mitogenesis n vivo. Studies using 
selective inhibitors of either the cyclooxygenase pathway or the 
lipoxygenase pathway to block liver regeneration will indicate 
whether these metabolites, asopposed to free arachidonic acid 
itself, are critical for the observed stimulation of DNA synthesis. 
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